TORL Biotherapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, TORL Biotherapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
TORL Biotherapeutics: 8 sponsored US clinical trials, 5 recruiting.
TORL Biotherapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 5 trials.
Upper-quartile sponsor footprint
TORL Biotherapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
NCT07439653
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
NCT07322094
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
NCT05156866
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
NCT05159440
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 1 |
What is open in the TORL Biotherapeutics pipeline
5 recruiting of 8 indexed (63% open).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
TORL Biotherapeutics: open-pipeline peers nationwide
Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.
TORL Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 63% open enrollment (± trial volume)
- Canadian Cancer Trials Group · 63% recruiting · 16 trials
- CellSight Technologies · 63% recruiting · 8 trials
- Cook Children's Health Care System · 63% recruiting · 8 trials
- Nurix Therapeutics · 63% recruiting · 8 trials
Related
What to do with this TORL Biotherapeutics page
8 registered trials is a research-attention snapshot, not an endorsement of TORL Biotherapeutics or any single study.
- 5 of TORL Biotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition TORL Biotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
TORL Biotherapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.